open access

Vol 4, No 2 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-04-28
Get Citation

Vitamin D receptor gene polymorphisms and the risk of coronary artery disease in a Polish population with type 2 diabetes mellitus and with normal glucose metabolism

Maciej T. Małecki, Jan Skupień, Małgorzata Waluś, Małgorzata Owczarek, Wojciech Czogała, Przemysław Miarka, Tomasz Klupa, Jacek Sieradzki
Diabetologia Praktyczna 2003;4(2):137-144.

open access

Vol 4, No 2 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-04-28

Abstract

INTRODUCTION. Vitamin D plays an important role in calcium and phosphates metabolism. There is evidence that this steroid modifies the risk factors of coronary artery disease (CAD). Thus genes that are involved in vitamin D metabolism are good candidates for CAD in genetic studies. One of those genes vitamin D receptor (VDR). For example, an association between one of many VDR polymorphisms (BsmI) and CAD was shown in a German population, particularly among patients with type 2 diabetes mellitus (T2DM).
AIM. To search for the association of FokI, ApaI, BsmI, and TaqI polymorphisms of the VDR gene with CAD in two Polish cohorts of unrelated individuals: with and without T2DM.
MATERIAL AND METHODS. Overall, we included 521 individuals into this analysis: 292 patients with T2DM and 229 without T2DM. The diagnosis of CAD in both groups was based on a questionnaire and patient medical records. All individuals included into the analysis were previously genotyped for frequent VDR polymorphisms: FokI, ApaI, BsmI, and TaqI. Alleles were defined based on restriction fragment length polymorphism method (RFLP). Since variants of ApaI, BsmI, and TaqI polymorpshisms were in very strong linkage disequilibrium, three loci haplotypes could be assigned to phase-unknown individuals with high degree of confidence. Differences in distribution were assessed by c2 test.
RESULTS. In the group of T2DM patients, the diagnosis of CAD was established in 35.93% individuals, while in the group without T2DM this number was 26.32%. There was no difference between the carriers of the different genotypes of the four examined markers with respect to the frequency of CAD diagnosis of each group both separately or when analyzed jointly. We observed, however, that the carriers of bAT/baT three point haplotype combinations were diagnosed with CAD less frequently than the carriers of all other haplotype combination: 25.58% vs. 37.75%; p = 0.125 in T2DM group, 14.29% vs. 27.86% in the group without T2DM; p = 0.126 and 21.13% vs. 33.33%; p = 0.03 in the joint analysis of both groups, respectively.
CONCLUSION. The results of our study suggest that polymorphisms of the VDR gene may influence the risk of CAD in a Polish population.

Abstract

INTRODUCTION. Vitamin D plays an important role in calcium and phosphates metabolism. There is evidence that this steroid modifies the risk factors of coronary artery disease (CAD). Thus genes that are involved in vitamin D metabolism are good candidates for CAD in genetic studies. One of those genes vitamin D receptor (VDR). For example, an association between one of many VDR polymorphisms (BsmI) and CAD was shown in a German population, particularly among patients with type 2 diabetes mellitus (T2DM).
AIM. To search for the association of FokI, ApaI, BsmI, and TaqI polymorphisms of the VDR gene with CAD in two Polish cohorts of unrelated individuals: with and without T2DM.
MATERIAL AND METHODS. Overall, we included 521 individuals into this analysis: 292 patients with T2DM and 229 without T2DM. The diagnosis of CAD in both groups was based on a questionnaire and patient medical records. All individuals included into the analysis were previously genotyped for frequent VDR polymorphisms: FokI, ApaI, BsmI, and TaqI. Alleles were defined based on restriction fragment length polymorphism method (RFLP). Since variants of ApaI, BsmI, and TaqI polymorpshisms were in very strong linkage disequilibrium, three loci haplotypes could be assigned to phase-unknown individuals with high degree of confidence. Differences in distribution were assessed by c2 test.
RESULTS. In the group of T2DM patients, the diagnosis of CAD was established in 35.93% individuals, while in the group without T2DM this number was 26.32%. There was no difference between the carriers of the different genotypes of the four examined markers with respect to the frequency of CAD diagnosis of each group both separately or when analyzed jointly. We observed, however, that the carriers of bAT/baT three point haplotype combinations were diagnosed with CAD less frequently than the carriers of all other haplotype combination: 25.58% vs. 37.75%; p = 0.125 in T2DM group, 14.29% vs. 27.86% in the group without T2DM; p = 0.126 and 21.13% vs. 33.33%; p = 0.03 in the joint analysis of both groups, respectively.
CONCLUSION. The results of our study suggest that polymorphisms of the VDR gene may influence the risk of CAD in a Polish population.
Get Citation

Keywords

vitamin D receptor; gene; coronary artery disease; type 2 diabetes mellitus

About this article
Title

Vitamin D receptor gene polymorphisms and the risk of coronary artery disease in a Polish population with type 2 diabetes mellitus and with normal glucose metabolism

Journal

Clinical Diabetology

Issue

Vol 4, No 2 (2003): Practical Diabetology

Pages

137-144

Published online

2003-04-28

Bibliographic record

Diabetologia Praktyczna 2003;4(2):137-144.

Keywords

vitamin D receptor
gene
coronary artery disease
type 2 diabetes mellitus

Authors

Maciej T. Małecki
Jan Skupień
Małgorzata Waluś
Małgorzata Owczarek
Wojciech Czogała
Przemysław Miarka
Tomasz Klupa
Jacek Sieradzki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl